VP Heather Livingston's training on DermaStem™ from the 2011 Stemtech Convention.- Part 1 ... Our breakthrough serum revitalizes the skin at the cellular level, to restore and maintain the skin's youthful vibrance. DermaStem™'s all-natural ingredients provide the ideal environment for the regenerative properties of the adult stem cells, supporting the natural process of skin renewal.

View original post here:
Turning Science Into Action with Heather Livingston - Part 1 http://www.miraclecell.info - Video

DOWNLOAD HERE: newsdirect.nma.com.tw US scientists have succeeded in producing embryonic stem cells using a new cloning technique. They injected genetic material from a diabetic patient's skin cell into a donor egg, and stimulated it to develop enough so stem cells could be extracted. The result is stem cells with 69 chromosomes - one set of 23 more than a normal human's 46 - meaning they cannot be used for cell replacement therapy yet.

Link:
US scientists unveil new cloning method for embryonic stem cells - Video

Insight into the world of stem cell research. This 15-minute film uses innovative hand-drawn animation, beautiful cell photography and documentary interviews to capture the fascination and complexity of this cutting-edge area of science.

Read more from the original source:
A Stem Cell Story - Video

Transplanted adult stem cells have been found to reverse paralysis associated with spinal cord injuries in lab rats, a new study finds.

More:
Electro-Medicine : Biological Physics - Paralysis Spinal Chord Injury Treatment - Video

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

The $3 billion California stem cell agency likes to align itself with the very best science. And as of today it is also hooked up with the best lobbyist in California – at least based on earnings.

CIRM hires many firms to perform work, given its unusual needs, rather than building a large and relatively permanent staff. The tasks of the outside contractors range from publishing the annual report to grant review matters. Today Laurel Rosenhall of The Sacramento Bee reported that one of the firms that CIRM has hired now ranks as the No. 1 lobbyist in California, based on its earnings.

The firm of Nielsen, Merksamer, Parrinello, Gross & Leoni pulled down nearly $5 million during the first three quarters of this year. The firm knocked KP Public Affairs out of the top spot, which it had held for at least the last 10 years.

Nielsen has had a contract with CIRM since its earliest days in 2005, but it doesn't amount to much in the scope of Nielsen's business. According to the latest CIRM report on outside contracting, Nielsen was paid $79,984 during the fiscal year 2010-2011 for services that also extended into the current fiscal year. The report did not list payments for earlier years, but it is our recollection that Nielsen was paid about $50,000 every year since 2005. It is not known whether the firm continues to hold a contract for the current fiscal year.

One of Nielsen's partners, Gene Erbin, was one of the drafters of Prop. 71, the ballot initiative that created the California stem cell agency in 2004. Merck and Pfizer, in addition to CIRM, are among the firm's clients.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The prestigious Institute of Medicine earlier this month kicked off its $700,000 study of the California stem cell agency minus an important perspective – the view directly from California.

None of the persons on the 13-member panel evaluating the performance of the $3 billion enterprise comes from California. The reasons for that are not clear. The IOM is all but mum on the matter.

One could argue that it is not necessary to be geographically located in California to determine whether CIRM is working at peak performance. However, some conditions do exist in California that are difficult for many others to grasp. They include its state budget crisis that has now placed the once Golden State at the bottom of the heap in terms of its credit. Some even liken it to Greece. Obviously that situation can be understood in the abstract by reading The Sacramento Bee and the Los Angeles Times. But the intensity and emotion surrounding that issue and others are difficult to comprehend for many folks living in more blessed states.

Count among the other volatile issues the cutbacks in the state's once vaunted higher education system, including the University of California, which showed its back to students by increasing tuition by nearly 18 percent this fall. Couple that with a visceral antipathy -- and that is putting it mildly -- among some Californians to what they regard as execessive state salaries, including those at the stem cell agency.

What does all this have to with financing stem cell research through an agency that was supposed to have a guaranteed stream of income isolated from mischief that could be wreaked by the governor or legislature. It turns out that CIRM's cash flow is not as guaranteed as its backers believed. Instead of issuing bonds, the state is going to finance the agency over the next 18 months with commercial paper, if necessary. That's because Gov. Jerry Brown wants to reduce the interest costs on state borrowing, which have risen sharply and now consume 8 percent of the state budget along with funds that could otherwise go to educate California's children, among other things.

Brown's parsimony is famous. During his first term in office, he denied pay raises to state college professors, saying they are amply rewarded through "psychic income." More recently, he objected to out-of-state travel by CIRM staff. Too much "lollygagging in London on the taxpayer's dime," a Brown spokesman said. CIRM Chairman Jonathan Thomas promptly cut travel in the chairman's office by 50 percent and asked CIRM President Alan Trounson to do the same for the rest of the staff.

It is an environment that can be difficult to navigate under the best of circumstances. It places limitations on the stem cell agency and tends to focus its operations and funding in different directions than might be the case if California's economic climate were rosier.

The IOM has no real response to the question of why no Californian is on the panel. The California Stem Cell Report last week asked the institute whether an overt decision had been made to exclude persons from California. The IOM did not answer directly. Instead it referred to a generic description of how panel members are selected. The institute's unwillingness to address the specific question does not speak well for the openness and transparency of the IOM examination of CIRM.

Currently the IOM does have a comment period available on the selection of the panel members, who will not become official for another three days. Interested parties can make their views known to the IOM by using this link.

A Californian or two on the IOM panel would help to bring a valuable, broader perspective to this important study, which is sure to affect the future of the state's stem cell research and voter approval of another possible multibillion dollar bond issue in the next few years.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The Second Conference on Stem cells and Regenerative Medicine. Arranged by the Stem Cell Unit, Anatomy Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Link:
The Second Conference on Stem cells and Regenerative Medicine_2011.wmv - Video

Treatment of Depression More Than Triples in the US Over the Last 10 Years

Among people receiving treatment for depression in the US, the percentage of those on antidepressant medication has risen dramatically, while fewer are opting for time on the couch in psychotherapy.

The number of Americans treated for depression soared from 1.7 million to 6.3 million between 1987 and 1997, and the proportion of those receiving antidepressants doubled.

The researchers attributed the sharp increases to the emergence of aggressively marketed new drugs like Prozac, the rise in managed care and an easing of the stigma attached to the disease.

The study found that the share of patients who used antidepressant medication climbed from 37% to nearly 75%. At the same time, the proportion who received psychotherapy declined from 71% to 60%.

The publicizing of newer antidepressants that have fewer side effects - such as Prozac, which was introduced in late 1987 - has helped make patients more willing to seek treatment, the researchers said. This publicity has included pharmaceutical industry efforts to market the drugs directly to consumers and public-awareness campaigns about depression. Read more...

Ayurtox for Body Detoxification

Source:
http://feeds.feedburner.com/integratedmedicine

"I thought there was absolutely no hope and that I was destined to pass away." Ron was diagnosed with COPD in 200.

Read the original here:
Before/After Stem Cell for COPD: From Unable to Walk, to Dancing at My Daughter's Wedding - Video

WXII12 went inside animal hospital room in Greensboro...

Go here to read the rest:
Latest Stem Cell Therapy For Your Pets - Video

Elaine Fuchs, Ph.D. Rebecca C. Lancefield Professor, The Rockefeller University, Mammalian Cell Biology

Originally posted here:
Stem Cells and Their Lineages in Skin - Video

Treating cancer is BIG business in America -- in fact, it's a $200 billion a year business. Yet 98 percent of conventional cancer treatments not only FAIL miserably, but are also almost guaranteed to make cancer patients sicker.

What's worse: The powers are suppressing natural cancer cures that could help tens of thousands of people get well and live cancer free with little or no dependence on drugs, surgery and chemotherapy.

The treatment of cancer in the U.S. is one of the most bald-faced cover-ups in medical history. Enough is enough! You deserve to know the truth about the criminality of oncologists and about the dangers of chemotherapy, conventional cancer treatments and the cancer "business."

Chemotherapy kills more than cancer
Want proof? Did you know that 9 out of 10 oncologists would refuse chemotherapy if they had cancer? That's up to 91% -- a huge percentage that clearly shines a light on the truth: chemotherapy kills. Conventional oncologists are not only allowing this to happen, but they're also bullying many patients into chemotherapy and surgery right after their diagnoses. Read more...

Ayurtox for Body Detoxification

Source:
http://feeds.feedburner.com/integratedmedicine

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Taking quality multivitamins is a great way to supplement one's diet with high doses of nutrients that are often lacking in modern-day food. And a new study out of Sweden has found that women who take multivitamins help to reduce their overall risk of cardiovascular disease and heart attack.

For ten years, Dr. Susanne Rautiainen and her colleagues from the Karolinska Institutet in Stockholm monitored 31,671 women with no history of heart disease and 2,262 women with heart disease to observe their progression in overall health. Roughly 60 percent of women from both groups took some kind of dietary supplement.

At the completion of the study, 3.4 percent of the women who had no heart disease to begin with, but who did not take any dietary supplements, ended up having heart attacks. In contrast, only 2.6 percent of women from the same group who did take a multivitamin had heart attacks. Statistically, the multivitamin group exhibited a 27 percent less chance of having a heart attack. Read more...

Cardiofy Heart Care Supplement

Source:
http://feeds.feedburner.com/integratedmedicine

agorafinancial.com | contact us | login

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

International Stem Cell Corporation (OTCBB: ISCO) announces today successful completion of the first series of preclinical studies designed to support the safety and utility of neuronal cells derived from human parthenogenetic stem cell line (hpSC). These initial experiments, demonstrating that the derived neuronal cells were able to survive in mice brains without giving rise to tumors, represent a key milestone towards possible therapeutic applications including treating Parkinson's disease.


Dr. Albrecht Müller, Professor at the Institute of Medical Radiology and Cell Research, Würzburg University (Germany), commented: "Human parthenogenetic stem cells are potentially very promising candidates for use in regenerative medicine primarily because of the possibility that they immune-match a large number of recipients. The result of these safety and survival studies is a very important step along the path towards the clinical use of such cells."


Although most cases of Parkinson's disease occur in people with no family history of the disease, a number of genetic mutations have nevertheless been identified with the disease. While the inheritance pattern is largely unknown, as a condition with a genetic component "autologous" treatment, that is to say treatment using the patient's own cells, is far from ideal and does not offer the potential of a cure. To treat Parkinson's disease successfully a source of cells free of the mutated genes is necessary. Human parthenogenetic stem cells provide this source, as well as superior immune-matching capabilities.


ISCO currently has the world's largest collection of human parthenogenetic stem cells including heterozygous examples, where the cells immune match the donor as is the case with induced pluripotent stem cells (iPS), and homozygous examples which immune-match millions of individuals. ISCO is actively expanding this collection of cell lines and creating a "bank" of homozygous human parthenogenetic stem cells that can be used as a platform to not only reduce the chances of tissue rejection, but also make cellular-based therapies economically more viable.


Dr. Ruslan Semechkin, ISCO's Vice President, commented: "One of ISCO's main therapeutic targets is treatment of Parkinson's disease, a common neurodegenerative disease in the US, where the current standard of care is designed mostly to treat the symptoms, but not the disease. These results clearly represent an important step towards the therapeutic application of human parthenogenetic stem cells derived cells in addressing the basic underlying mechanisms and potentially transforming the treatment of neurodegenerative diseases."


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCellTM. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com 


To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


Forward-looking Statements
Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward- looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.


International Stem Cell Corporation
Kenneth C. Aldrich, co -Chairman
760-940-6383
kaldrich@intlstemcell.com
Or:
Dr. Ruslan Semechkin, Vice President
760-940-6383
ras@intlstemcell.com
Or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

signalsskincareoffer.com Find out More Check out the Website

Read more from the original source:
Signals Stem Cell Skin Care Anti Aging Skin Care - Video

http://www.ibioseminars.org During embryogenesis, a single fertilized oocyte gives rise to a multicellular organism whose cells and tissues have adopted differentiated characteristics or fates to perform the specified functions of each organ of the body. As embryos develop, cells that have acquired their particular fate proliferate, enabling tissues and organs to grow

Follow this link:
Elaine Fuchs Part 1: Introduction to Stem Cells English Subtitle